Literature DB >> 10944369

Abortion with mifepristone and misoprostol: regimens, efficacy, acceptability and future directions.

E P Newhall1, B Winikoff.   

Abstract

Mifepristone at a dose of 600 mg followed by 400 microg misoprostol orally has been used for early abortion by hundreds of thousands of women with success rates at </=49 days' gestation ranging from 92% to 97%. Newer regimens may prove simpler than this standard regimen and may serve a larger number of patients. Vaginal rather than oral administration of misoprostol may have advantages, including improvement in the efficacy of mifepristone regimens at >49 days' gestation. A lower mifepristone dose of 200 mg and in-home self-administration of misoprostol both appear safe and effective. Although most research protocols have used ultrasonography to confirm gestational age, the method can be provided safely without routine reliance on ultrasonography. Acceptability of the method to care providers and to patients has been high in all studies. The introduction of medical abortion into general medical practice in the United States will teach us much about the practical aspects of service provision.

Entities:  

Keywords:  Abortion, Drug Induced; Abortion, Induced; Americas; Biology; Developed Countries; Endocrine System; Family Planning; Fertility Control, Postconception; Health; Hormone Antagonists; Hormones; Literature Review; Misoprostol; North America; Northern America; Physiology; Prostaglandins; Prostaglandins, Synthetic; Public Health; Ru-486; Safety; United States

Mesh:

Substances:

Year:  2000        PMID: 10944369     DOI: 10.1067/mob.2000.107950

Source DB:  PubMed          Journal:  Am J Obstet Gynecol        ISSN: 0002-9378            Impact factor:   8.661


  9 in total

1.  Mifepristone increases mRNA translation rate, triggers the unfolded protein response, increases autophagic flux, and kills ovarian cancer cells in combination with proteasome or lysosome inhibitors.

Authors:  Lei Zhang; Maria B Hapon; Alicia A Goyeneche; Rekha Srinivasan; Carlos D Gamarra-Luques; Eduardo A Callegari; Donis D Drappeau; Erin J Terpstra; Bo Pan; Jennifer R Knapp; Jeremy Chien; Xuejun Wang; Kathleen M Eyster; Carlos M Telleria
Journal:  Mol Oncol       Date:  2016-05-17       Impact factor: 6.603

2.  Early abortion in family medicine: clinical outcomes.

Authors:  Ian M Bennett; Margaret Baylson; Karin Kalkstein; Ginger Gillespie; Scarlett L Bellamy; Joan Fleischman
Journal:  Ann Fam Med       Date:  2009 Nov-Dec       Impact factor: 5.166

3.  Instability of misoprostol tablets stored outside the blister: a potential serious concern for clinical outcome in medical abortion.

Authors:  Veronique Berard; Christian Fiala; Sharon Cameron; Teresa Bombas; Mirella Parachini; Kristina Gemzell-Danielsson
Journal:  PLoS One       Date:  2014-12-15       Impact factor: 3.240

4.  Medical abortions among university students in Ghana: implications for reproductive health education and management.

Authors:  Nana Nimo Appiah-Agyekum
Journal:  Int J Womens Health       Date:  2018-09-05

5.  Exploring the impact of mifepristone's risk evaluation and mitigation strategy (REMS) on the integration of medication abortion into US family medicine primary care clinics✰,✰✰.

Authors:  Na'amah Razon; Sarah Wulf; Citlali Perez; Sarah McNeil; Lisa Maldonado; Alison Byrne Fields; Diana Carvajal; Rachel Logan; Christine Dehlendorf
Journal:  Contraception       Date:  2022-02-04       Impact factor: 3.051

6.  Mifepristone (RU-486®) as a Schedule IV Controlled Drug-Implications for a Misleading Drug Policy on Women's Health Care.

Authors:  Yi-Ping Hsieh; Yun-Ju Wang; Ling-Yi Feng; Li-Tzy Wu; Jih-Heng Li
Journal:  Int J Environ Res Public Health       Date:  2022-07-08       Impact factor: 4.614

7.  Role of Combination OF Mifepristone and Misoprostol Verses Misoprostol alone in Induction of Labour in Late Intrauterin Fetal Death: A Prospective Study.

Authors:  Subrat Panda; Vandana Jha; Santa Singh
Journal:  J Family Reprod Health       Date:  2013-12

8.  The incidence of induced abortion in Kinshasa, Democratic Republic of Congo, 2016.

Authors:  Sophia Chae; Patrick K Kayembe; Jesse Philbin; Crispin Mabika; Akinrinola Bankole
Journal:  PLoS One       Date:  2017-10-02       Impact factor: 3.240

9.  Comparison of Outcomes before and after Ohio's Law Mandating Use of the FDA-Approved Protocol for Medication Abortion: A Retrospective Cohort Study.

Authors:  Ushma D Upadhyay; Nicole E Johns; Sarah L Combellick; Julia E Kohn; Lisa M Keder; Sarah C M Roberts
Journal:  PLoS Med       Date:  2016-08-30       Impact factor: 11.069

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.